The early experimental evidence showed that bempedoic acid led to LDL–receptor upregulation, decreased LDL-C, attenuation of atherosclerosis, reduced hepatic lipids and body weight and improved glycaemic control [18••, 20]. On this matter, both the genetic inhibition of ACLY in hepatocytes and the pharmacological inhibition of ACLY by using bempedoic acid suppress fatty acid and cholesterol synthesis and increase fatty acid oxidation, while reducing glucose intolerance, liver steatosis and ballooning, without increasing circulating triglycerides. The gene discussed is ACLY; the disease is atherosclerosis.